Immusoft to Showcase Promising Data from Engineered B Cell Therapy at WORLDSymposium 2025
Immusoft to Showcase Promising Data from Engineered B Cell Therapy at WORLDSymposium 2025
Immusoft Corporation, a trailblazer in cell therapy focusing on rare diseases, has announced an exciting presentation lined up for the upcoming WORLDSymposium™ 2025. Scheduled to be held in San Diego from February 3-7, 2025, Immusoft will present compelling data related to its first engineered B cell therapy through an oral and poster presentation.
Key Details of the Presentation
The oral presentation is set for February 7 at 9:00 AM PST. Dr. Paul Orchard, a leading figure in pediatric blood and marrow transplantation at the University of Minnesota Medical School, will share insights titled “Safety and initial activity of autologous human B cells genetically engineered to express human iduronidase using the Sleeping Beauty transposon system: Results from a first-in-human clinical trial in subjects with MPS I.” This study represents a breakthrough in the treatment of mucopolysaccharidosis type I (MPS I), a rare lysosomal storage disease presently lacking effective therapies.
In addition, a dedicated poster presentation will also take place on February 5, 2025, from 3:30 PM to 5:30 PM PST. Both formats aim to disseminate critical findings from the pioneering trial that marks the first human application of genetically engineered B cell technology to combat MPS I.
The Promise of Engineered B Cells
Immusoft’s innovative approach involves utilizing B cells as biofactories for therapeutic protein delivery. This novel modality shows potential benefits such as durability and repeatability in treatment methodology. Their lead drug candidate, ISP-001, represents a significant advancement in medical science; it’s the first engineered B cell entering human clinical trials and aims to provide a first-in-class therapy for MPS I.
The trial focusing on ISP-001 is groundbreaking in several ways. Notably, the patient received the engineered B cells without undergoing toxic preconditioning or requiring immunosuppression, processes typically associated with gene therapy that can lead to severe side effects. By avoiding these invasive steps, Immusoft’s therapy may present a safer alternative for patients in need of effective treatments.
Currently, MPS I patients face a considerable lack of treatment options that combine efficacy with convenience. Standard care often revolves around enzyme replacement therapies (ERT) or hematopoietic stem cell transplants (HSCT), both of which come with limitations. The unique properties of B cells — particularly their high-level protein production capability, natural bone marrow engraftment without harsh preconditioning, and versatility to manufacture various types of proteins — make them a promising solution for treating numerous medical conditions.
Immusoft's Vision for the Future
Immusoft’s overarching goal is to reshape the landscape of treatment for rare diseases through their innovative platform, referred to as Immune System Programming (ISP™). This technology offers a personalized approach, transforming a patient’s B cells into miniature factories designed to produce gene-encoded medicines intended for sustained therapeutic delivery. By reprogramming these cells, Immusoft envisions a future where patients might benefit from long-lasting solutions to ailments that once had limited or ineffective treatment options.
For further information regarding Immusoft and its contributions to this exciting field, interested individuals can visit their website at www.immusoft.com. As they continue to break new ground in the realm of cell therapy, the upcoming presentation at WORLDSymposium 2025 will likely be crucial in garnering attention from the medical community and industry stakeholders alike.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.